New drug shows promise for rare blistering skin condition

NCT ID NCT02226146

Completed Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a drug called bertilimumab in 11 adults aged 60 and older with newly diagnosed bullous pemphigoid, a condition that causes painful blisters. The main goals were to check safety and see if the drug helps control the disease. While results may show some benefit, this is not a cure, and patients typically need ongoing treatment to manage the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blister bullous pemphigoid skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEMPHIGOID, BULLOUS

Contacts and locations

Show contact details

Locations

Research Site

Iowa City, Iowa, United States
Research Site

Buffalo, New York, United States
Research Site

New York, New York, United States
Research Site

Durham, North Carolina, United States
Research Site

Cleveland, Ohio, 10900, United States
Research Site

Salt Lake City, Utah, United States
Research Site

Ramat Gan, 5262100, Israel
Research Site

Tel Aviv, 64239, Israel